Gedeon Richter's Reguлон Contraceptive Pills: Patient Information Updated
Gedeon Richter Plc. has issued updated patient information for its combined oral contraceptive, Reguлон, containing desogestrel and ethinylestradiol. The medication is used to prevent pregnancy by affecting ovulation and cervical mucus.
Budapest, Hungary – Gedeon Richter Plc., a pharmaceutical company, has released updated patient information regarding its combined oral contraceptive, Reguлон. The medication contains desogestrel (150 mcg) and ethinylestradiol (30 mcg) as its active ingredients.
Reguлон is indicated for the prevention of pregnancy. Its mechanism of action involves suppressing ovulation and increasing the viscosity of cervical mucus, which hinders sperm penetration into the uterus. Additionally, the use of combined oral contraceptives may lead to more regular menstrual cycles and reduce the pain and intensity of menstrual bleeding, potentially lowering the risk of iron-deficiency anemia.
The patient leaflet emphasizes that while Reguлон is a highly effective contraceptive, it does not protect against HIV infection or other sexually transmitted diseases. Patients are strongly advised to read the instructions thoroughly and discuss any questions or concerns with their healthcare provider before commencing use.
The information also details contraindications and special precautions. This includes risks related to blood clots, specific medical conditions such as diabetes or hypertension, liver or breast conditions, and interactions with other medications. Patients are instructed to discontinue use and contact a physician immediately if any of the listed conditions arise during treatment.